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Abstract
Introduction The melanocortin peptides have marked anti-
inflammatory potential, primarily through inhibition of
proinflammatory cytokine production and action on phagocytic
cell functions. Gout is an acute form of arthritis caused by the
deposition of urate crystals, in which phagocytic cells and
cytokines play a major pathogenic role. We examined whether
alpha-melanocyte-stimulating hormone (α-MSH) and its
synthetic derivative (CKPV)2 influence urate crystal-induced
monocyte (Mo) activation and neutrophil responses in vitro.
Methods Purified Mos were stimulated with monosodium urate
(MSU) crystals in the presence or absence of melanocortin
peptides. The supernatants were tested for their ability to induce
neutrophil activation in terms of chemotaxis, production of
reactive oxygen intermediates (ROIs), and membrane
expression of CD11b, Toll-like receptor-2 (TLR2) and TLR4. The
proinflammatory cytokines interleukin (IL)-1β, IL-8, and tumor
necrosis factor-alpha (TNF-α) and caspase-1 were determined
in the cell-free supernatants. In parallel experiments, purified
neutrophils were preincubated overnight with or without
melanocortin peptides before the functional assays.
Results The supernatants from MSU crystal-stimulated Mos
exerted chemoattractant and priming activity on neutrophils,
estimated as ROI production and CD11b membrane
expression. The supernatants of Mos stimulated with MSU in the
presence of melanocortin peptides had less chemoattractant
activity for neutrophils and less ability to prime neutrophils for
CD11b membrane expression and oxidative burst. MSU crystal-
stimulated Mos produced significant levels of IL-1β, IL-8, TNF-α,
and caspase-1. The concentrations of proinflammatory
cytokines, but not of caspase-1, were reduced in the
supernatants from Mos stimulated by MSU crystals in the
presence of melanocortin peptides. Overnight incubation of
neutrophils with the peptides significantly inhibited their ability to
migrate toward chemotactic supernatants and their capacity to
be primed in terms of ROI production.
Conclusions α-MSH and (CKPV)2 have a dual effect on MSU
crystal-induced inflammation, inhibiting the Mos' ability to
produce neutrophil chemoattractants and activating
compounds and preventing the neutrophil responses to these
proinflammatory substances. These findings reinforce previous
observations on the potential role of α-MSH and related
peptides as a new class of drugs for treatment of inflammatory
arthritis.Page 1 of 8
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Alpha-melanocyte-stimulating hormone (α-MSH) is an endog-
enous tridecapeptide with multiple effects on host cells. The
synthetic peptide inhibits inflammatory responses in
experimental models of acute and chronic disorders, including
bowel diseases, allergy, adjuvant arthritis, and sepsis [1-4]. α-
MSH interacts with host cells through recognition of specific
melanocortin receptors (MCRs 1 to 5). Its anti-inflammatory
action depends primarily on inhibition of cytokine production
by target cells. This is achieved by preventing the activation of
nuclear transcription factor-kappa-B (NF-κB) (reviewed in [4]).
Several leukocyte functions, including reactive oxygen inter-
mediate (ROI) generation and release of proteolytic enzymes,
are also influenced by α-MSH. Nitric oxide production and the
expression of adhesion molecules are likewise inhibited in
both neutrophils and monocytes (Mos) [5,6]. α-MSH inhibits
human neutrophil migration and several other interleukin-8 (IL-
8)-induced biological responses [7-9]; inhibition of antigen-
stimulated lymphocyte proliferation has been reported also
[10]. The significant role of α-MSH and related peptides in
immune/inflammatory responses and their ability to prevent
inflammation-mediated tissue injury suggest these molecules
as a potential new class of anti-inflammatory drugs. However,
with a view to this use, cost-effective stable analogs need to
be developed.
Previous observations indicated that the anti-inflammatory
message sequence of α-MSH [1-13] resides in the C-terminal
tripeptide Lys-Pro-Val (MSH 11-13 or KPV) [11]. A dimer
obtained by inserting a Cys-Cys linker between two units of
KPV, (CKPV)2, inhibited tumor necrosis factor-alpha (TNF-α)
production by lipopolysaccharide (LPS)-stimulated human leu-
kocytes with potency similar to the stable α-MSH analog
[Nle4-dPhe7]-α-MSH (NDP-α-MSH) and effectiveness
greater than KPV. Effectiveness was similar in vivo: (CKPV)2
markedly inhibited circulating TNF-α after intravenous injection
of LPS and significantly reduced TNF-α and NO2- concentra-
tions in plasma and in the peritoneal cavity in a rat model of
LPS-induced peritonitis [12].
We recently reported that (CKPV)2 in vitro reduced several
human neutrophil activities important for the host inflammatory
response. These inhibitory effects included cell migration, ROI
production, proinflammatory cytokine synthesis and secretion,
and expression of adhesion molecules [9].
Gout is an acute form of arthritis causing substantial inflamma-
tion and involving tissue deposition of monosodium urate
(MSU) crystals. Both Mos and neutrophils are important in
pathogenesis. Recent observations suggest that MSU crys-
tals act as danger signals with the ability to activate caspase-
1 in an NALP-3 inflammosome-dependent manner, with pro-
duction and release of active IL-1β [13]. In this model, the sec-
ond phase of the inflammatory response is driven by the IL-1β/
IL-1R pathway with activation of an MyD88-dependent signal-
ing pathway and NF-κB activation followed by production of
inflammatory mediators that elicit neutrophil recruitment into
the joints, characteristic of the acute gouty inflammation [14].
The importance of Mos and neutrophils in the pathogenesis of
acute gout suggests that α-MSH and related peptides control
MSU-induced inflammation. This was suggested by Getting
and colleagues [15,16], who showed that melanocortins had
protective action in a rat model of gouty arthritis. Therefore, we
examined whether α-MSH and the synthetic melanocortin
(CKPV)2 influenced MSU crystal-induced human Mo activa-
tion and human neutrophil responses in vitro.
Materials and methods
Reagents
The peptides (CKPV)2 and α-MSH [1-13], N-acetylated and
C-amidated, were kindly provided by Paolo Grieco, Depart-
ment of Pharmaceutical and Toxicological Chemistry, Univer-
sity of Naples Federico II, Italy. Lymphoprep gradient (density
1.077 g/mL) and Nycoprep 1.068 gradient were purchased
from Axis-Shield (Oslo, Norway). Extra-low endotoxin fetal
bovine serum (FBS) was obtained from HyClone (Logan, UT,
USA). Hanks' balanced salt solution, RPMI 1640, penicillin,
streptomycin, glutamine, bovine serum albumin (BSA), N-
formyl-methionyl-leucyl-phenylalanine (FMLP), luminol (5-
amino-2,3-dihydro-1,4-phthalazinedione), and polymyxin B sul-
phate were from Sigma-Aldrich (St. Louis, MO, USA). Micro-
pore filters were from Millipore Corporation (Bedford, MA,
USA). The caspase-1 inhibitor z-YVAD-fmk was from Alexis
Biochemicals (Farmingdale, NY, USA). The phycoerythrinated
anti-Toll-like receptor-2 (TLR2), anti-TLR4, and anti-CD11b
monoclonal antibodies (mAbs) were from eBioscence, Inc.
(San Diego, CA, USA). Irrelevant class-matched mAbs used
as controls for nonspecific binding were from Becton, Dickin-
son and Company (Franklin Lakes, NJ, USA). The mAbs anti-
IL-1β and anti-IL-8 and the specific enzyme-linked immuno-
sorbent assay (ELISA) for IL-1β, IL-8, TNF-α, and caspase-1
were from R&D Systems (Abingdon, UK). MSU crystals were
prepared according to the method described by Murakami
and colleagues [17]. The crystals were sterilized by heating at
180°C for 2 hours, were resuspended in phosphate-buffered
saline (PBS) at a concentration of 10 mg/mL, and were veri-
fied free of endotoxin by the Limulus amoebocyte cell lysate
assay (Sigma-Aldrich).
Neutrophils and monocyte isolation and culture
Peripheral blood neutrophils were obtained by density gradi-
ent centrifugation (Lymphoprep) [18]. The purified cell popu-
lation consisted of greater than 95% pure, viable neutrophils,
assessed on the basis of morphology and Trypan blue exclu-
sion. In some experiments, purified neutrophils, at the appro-
priate density (2.5 × 106/mL), were incubated in polypropilene
tissue culture tubes (Corning Incorporated, Corning, NY,
USA) at 37°C in a humidified atmosphere of 5% CO2 for 18
hours in complete medium alone (see below), α-MSH 10-6 M,Page 2 of 8
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used in the functional assays as described below. Viability of
cells was always more than 95%.
Peripheral blood Mos were purified on a Nycoprep 1.068 gra-
dient (as described in detail by Boyum [19]), which routinely
yielded 85% to 90% Mo as assessed by Wright staining, non-
specific esterase staining, and (in some cases) immunofluo-
rescent staining for CD14; viability was more than 95% by
Trypan blue exclusion. Freshly isolated Mos were resus-
pended in RPMI 1640 containing 10% heat-inactivated FBS
(30 minutes at 56°C), 100 U/mL penicillin, 100 μg/mL strep-
tomycin, and 2 mM glutamine (complete medium) at 1 × 106
Mos/mL. The Mo suspensions were incubated in polystyrene
tissue culture flasks (cell growth area 25 cm2; Corning Incor-
porated) at 37°C in a 95% air-5% CO2 humidified atmosphere
for 24 hours in complete medium with or without MSU crystals
(1 mg/mL) and with or without the indicated concentrations of
α-MSH or (CKPV)2.
To check for artifacts of trace endotoxin contamination of MSU
crystals, the cells were incubated with MSU in the presence of
polymyxin B sulphate (10 μg/mL) in some experiments. In
three separate experiments, the caspase-1 inhibitor z-YVAD-
fmk was added to the cultured cells at a final concentration of
10 μM. The supernatants of cultured Mos were collected by
centrifugation (1,200 g for 15 minutes), were filtered through
a 0.22-μm filter (Millipore Corporation), and were stored at -
80°C until tested for their capacity to activate neutrophils and
for their content of IL-1β, IL-8, TNF-α, and caspase-1. The con-
centration of MSU crystals we used (1 mg/mL) had been
found to be optimal beforehand on a limited dose-response
curve (0.1, 1.0, and 10.0 mg/mL; data not shown) and was
similar to that used by others in similar experimental conditions
[16,20,21]. The viability of cultured Mos, determined by
Trypan blue exclusion, always exceeded 90%.
Chemotaxis
Neutrophil chemotaxis was examined using a modified Boyden
chamber assay with blind-well chambers and 3-μm micropore
filters [22]. Briefly, 200 μL of the cell suspension containing
3.75 × 106 neutrophils/mL in RPMI 1640 + 0.4% BSA was
layered on top of the filter, and the lower compartment was
filled with 200 μL of the supernatants from MSU-stimulated
Mos (SMMs) or the chemotactic factor FMLP (10-8 M final
concentration). After 120 minutes of incubation at 37°C in a
humidified atmosphere with 5% CO2, the filters were fixed
with ethanol and stained with hematoxylin-eosin. The chemo-
tactic response was determined by counting the number of
cells per high-power field which had migrated through the
entire thickness of the filter; duplicate chambers were used in
each experiment, and five fields were examined in each filter.
In all cases, the person scoring the assay was blind to the
experimental groupings. In some experiments, anti-IL-1β (1
μg/mL final concentration) or anti-IL-8 (4 μg/mL final concen-
tration) or the two mAbs together were added to the SMMs
before as chemoattractants.
Chemiluminescence
Luminol-amplified chemiluminescence (CL) was used to exam-
ine the phagocyte production of ROIs in response to MSU
crystals. To measure CL, 2.5 × 105 neutrophils were mixed in
3-mL polystyrene vials with 5 × 10-5 M luminol in a final volume
of 700 μL. The vials were placed in a Luminometer 1251 (LKB
Wallac, Turku, Finland) and allowed to equilibrate in the dark
for 5 minutes at 37°C, with intermittent shaking, and then the
background light output was recorded in millivolts. MSU crys-
tals (3 mg/mL final concentration) [23] were added using an
appropriate dispenser (1291; LKB Wallac), and the CL was
recorded continuously. The background counts were sub-
tracted from the values obtained after neutrophil stimulation.
To check the effect of the SMMs on CL production, neu-
trophils were preincubated with undiluted supernatants for 30
minutes at 37°C before the CL assay.
Surface expression of CD11b, TLR2, and TLR4
Flow cytometry of purified neutrophils was used to determine
the membrane expression of CD11b, TLR2, and TLR4. Phyco-
erythrin-conjugated mAbs were added to 100 μL of a purified
cell suspension (2 × 105 cells in PBS containing 0.1% NaN3
and 10% human AB serum). The staining reactions were
developed at 4°C for 30 minutes. After washing, the cells were
analyzed by flow cytometry (Becton Dickinson FACS II; Bec-
ton, Dickinson and Company). A relative measure of antigen
expression was obtained using the mean fluorescence inten-
sity, converted from a log to a linear scale, after subtracting the
cells' self-fluorescence and the fluorescence of cells incu-
bated with irrelevant isotype control mAbs.
Production of cytokines in vitro
IL-1β, IL-8, TNF-α, and caspase-1 protein concentrations were
determined in the cell-free supernatants using specific ELISA
in accordance with the procedures indicated by the manufac-
turer (R&D Systems).
Statistical analysis
The data are expressed as mean ± standard error of the mean.
Statistical analysis was done using the Student t test for
unpaired or paired data, as appropriate. A probability of less
than 0.05 was considered significant.
Results
Monosodium urate-stimulated monocytes produce 
neutrophil-activating mediators
Mos were incubated with MSU for 24 hours with or without α-
MSH or (CKPV)2; the cell-free supernatants were then tested
for their ability to induce neutrophil responses. The SMMs
showed significant chemotactic activity for neutrophils; this
was not due to contaminating LPS since the activity was no
different in SMMs from Mos cultured with polymyxin B sul-Page 3 of 8
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to or even greater than the standard chemoattractant FMLP
(Figure 1). MSU crystals induced CL production by
neutrophils. These SMMs also had a priming effect on neu-
trophils: when neutrophils were preincubated with the SMMs,
they showed an enhanced respiratory burst in response to a
challenge with MSU (Figure 2). In addition, neutrophils pre-
treated with the SMMs showed an increase in the membrane
expression of CD11b (Figure 3), whereas there was no
change in TLR2 and TLR4 membrane expression (data not
shown).
Complete analysis of the molecules responsible for the chem-
otactic and priming effects in the SMMs was beyond the
scope of this study. We focused on IL-1β, TNF-α, and IL-8, the
most important cytokines in gouty inflammation. As shown in
Figure 4, MSU crystals stimulated production of IL-1β, TNF-α,
and IL-8 by Mos. Preincubating SMMs with anti-IL-8 plus anti-
IL-1β mAbs significantly reduced, but did not abolish, their
chemotactic properties (62% inhibition); as shown in Figure 1,
Figure 1
Chemotactic properties of supernatants from monosodium urate (MSU) crystal-stimulated monocytes (SMMs)
crystal-stimulated monocytes (SMMs).  Monocytes were incubated for 
18 hours with MSU crystals (1 mg/mL) with or without alpha-melano-
cyte-stimulating hormone (α-MSH) (10-6 M) or (CKPV)2 (10-6 M) or pol-
ymyxin B (10 μg/mL). The cell-free supernatants from 10 separate 
experiments (two with polymyxin B) were used as chemoattractants for 
purified human neutrophils. In three separate experiments, SMMs were 
preincubated (15 minutes at room temperature) with anti-interleukin-1 
(anti-IL-1) or anti-IL-8 monoclonal antibodies or both before use as che-
moattractants. The chemotactic activity of the standard chemoattract-
ant N-formyl-methionyl-leucyl-phenylalanine (FMLP) (10-8 M) is shown. 
Results are expressed as number of neutrophils per high-power field 
(hpf). Bars denote mean ± standard error of the mean. *P < 0.05; **P < 
0.01; ***P < 0.005 versus SMMs.
Figure 2
Priming activity of supernatants from monosodium urate (MSU) crystal-sti ulated monocytes (SMMs) on chemiluminescence (CL) production by neutrophils
stimulated monocytes (SMMs) on chemiluminescence (CL) production 
by neutrophils.  Monocytes were incubated for 18 hours with MSU 
crystals (1 mg/mL) with or without alpha-melanocyte-stimulating hor-
mone (α-MSH) (10-6 M) or (CKPV)2 (10-6 M). The cell-free supernatants 
were used to pretreat purified neutrophils (30 minutes at 37°C) before 
analysis of their CL production in response to MSU (3 mg/mL). Results 
are expressed as peak CL values in millivolts. Bars denote mean ± 
standard error of the mean. °P < 0.001 versus RPMI; *P < 0.05 and 
**P < 0.01 versus SMMs.
Figure 3
Activity of supernatants from monosodium urate (MSU) crystal-stimu-lated monocyt s (SMMs) n CD11b me bran expression on hu an neutrophils
lated monocytes (SMMs) on CD11b membrane expression on human 
neutrophils.  Monocytes were incubated for 18 hours with MSU crys-
tals (1 mg/mL) with or without alpha-melanocyte-stimulating hormone 
(α-MSH) (10-6 M) or (CKPV)2 (10-6 M). Purified neutrophils were pre-
treated with the different SMMs or N-formyl-methionyl-leucyl-phenyla-
lanine (FMLP) (30 minutes at 37°C) before staining with the 
phycoerythrin-conjugated anti-CD11b monoclonal antibody. The 
results are expressed as mean fluorescence intensity (MFI) ± standard 
error of the mean, corrected for non-specific staining, from five separate 
experiments. °P < 0.001 versus RPMI; *P < 0.05 and **P < 0.01 ver-
sus SMMs.Page 4 of 8
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bition with anti-IL-8 and 18% inhibition with anti-IL-1β mAb).
In three separate experiments, IL-1β and IL-8 levels were
measured in supernatants from cultured Mos stimulated with
MSU in the presence of the caspase-1 inhibitor z-YVAD-fmk.
As shown in Figure 5, z-YVAD-fmk completely blocked MSU-
induced IL-1β production (95% inhibition) whereas IL-8 secre-
tion was only partially inhibited (23% inhibition).
Melanocortin peptides reduce the production of 
neutrophil-activating mediators by monosodium urate-
stimulated monocytes
The SMMs obtained in the presence of α-MSH or (CKPV)2
showed significant drops in their chemotactic capacity (Figure
1) and priming activity. CL production (Figure 2) and CD11b
membrane expression (Figure 3) were significantly lower than
in supernatants obtained without the peptides. The capacity of
Mos to produce proinflammatory cytokines in response to
MSU was reduced by α-MSH and (CKPV)2, whereas the
secretion of caspase-1, the enzyme responsible for converting
pre-IL-1β to the active form of the cytokine, was not affected
(Figure 4, bottom right). α-MSH did not further affect the inhib-
itory activity of z-YVAD-fmk on IL-1β production by MSU-stim-
ulated Mos but did induce further moderate inhibition of IL-8
production (30%) (Figure 5).
Melanocortin peptides inhibit neutrophil responses to 
activating mediators produced by monosodium urate-
stimulated monocytes
In parallel experiments, we examined the activity of the melano-
cortin peptides on neutrophil responses to the SMMs. Neu-
trophils were preincubated overnight with α-MSH or (CKPV)2
before the functional assays. As shown in Figure 6, this pre-
treatment significantly inhibited the neutrophils' ability to
migrate toward the SMMs whereas there was no effect on
Figure 4
Effects of alpha-melanocyte-stimulating hormone (α-MSH) and (CKPV)2 on inflammatory mediator production by monosodium urate (MSU)-stimu-lat d hum n monocytes
lated human monocytes.  Monocytes were incubated for 18 hours with MSU crystals (1 mg/mL) with or without α-MSH (10-6 M) or (CKPV)2 (10-6 M). 
Cytokine and caspase-1 protein concentrations were measured in the cell-free supernatants. Bars denote mean ± standard error of the mean. *P < 
0.05; **P < 0.02; ***P < 0.01 versus MSU. IL, interleukin; TNF-α, tumor necrosis factor-alpha.Page 5 of 8
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Effect of the caspase-1 inhibitor z-YVAD-fmk on inflammatory mediator production by monosod um urate (MSU) stimulated hu n monocytes
production by monosodium urate (MSU)-stimulated human monocytes.  
Monocytes were incubated for 18 hours with MSU crystals (1 mg/mL) 
with or without z-YVAD-fmk (10 mM) or alpha-melanocyte-stimulating 
hormone (α-MSH) (10-6 M) or the two together. Interleukin (IL)-1β and 
IL-8 concentrations were measured in the cell-free supernatants. 
Means ± standard errors of the mean of three separate experiments are 
presented.
MSU crystal-induced ROI production (data not shown). How-
ever, the overnight pretreatment made the cells less capable
of being primed by the SMMs in terms of ROI production (Fig-
ure 7).
Discussion
SMMs exert chemoattractant and priming activity on neu-
trophils, but SMMs obtained in the presence of the melanocor-
tin peptides had significantly less chemoattractant activity for
neutrophils and less ability to prime neutrophils for CD11b
membrane expression and the oxidative burst in response to
MSU crystals. Stimulation of Mos with MSU crystals induces
the production of proinflammatory and chemotactic sub-
stances [23-27]. Our interest was focused on IL-1, IL-8, and
TNF-α, the cytokines primarily involved in MSU crystal-medi-
ated inflammation. In the presence of the melanocortin pep-
tides, MSU crystal-stimulated Mos produced lower
concentrations of these cytokines. Inhibition of these key
mediators is probably at least partly responsible for the lower
chemotactic and activating properties of the supernatants.
Indeed, anti-IL-1β and anti-IL-8 mAbs showed similar inhibitory
action.
The present experiments do not clarify the mechanism of the
melanocortin peptides' inhibitory effect on Mos' ability to pro-
duce chemotactic and activating substances in response to
MSU. Recent observations indicate that MSU crystals may act
as danger signals that can activate caspase-1 in an NALP-3
inflammosome-dependent manner with production and
release of active IL-1β [13]. In this model, the second phase of
the inflammatory response is driven by IL-1β/IL-1R signaling
and MyD88-dependent NF-κB activation [14]. Consequently,
inflammatory mediators that elicit neutrophil recruitment char-
acteristic of acute gouty inflammation are produced.
In line with previous research [13], the present data indicate
the production and secretion of caspase-1 by MSU crystal-
stimulated Mos. Although melanocortin markedly reduced the
release of proinflammatory cytokines, the release of caspase-
1 was unaffected. This suggests that melanocortin peptides
do not influence the inflammosome-dependent phase of MSU
crystal stimulation. This is borne out by the observation that α-
Figure 6
Effect of alpha-melanocyte-stimulating hormone (α-MSH) and (CKPV)2 on neutrophil chemotaxis induced by supernatants from mo osodium urate-s imulated mo s
on neutrophil chemotaxis induced by supernatants from monosodium 
urate-stimulated monocytes.  Neutrophils were pretreated with or with-
out the peptides (10-6 M) for 18 hours before functional assays. Results 
are shown as number of cells per high-power field (hpf). Means ± 
standard errors of the mean of five separate experiments are presented. 
*P < 0.01 versus RPMI.Page 6 of 8
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ulated Mos in the presence of the caspase-1 inhibitor z-YVAD-
fmk.
Two molecular mechanisms by which melanocortin peptides
produce their anti-inflammatory effects might be relevant in
this experimental model of MSU-induced phagocyte stimula-
tion. First, the peptides prevent activation of NF-κB by a variety
of inflammatory stimuli (reviewed in [4]). Therefore, they may
inhibit MSU crystal-induced secretion of chemoattractants
and activating substances by inhibiting the second phase of
the inflammatory response mediated by NF-κB activation. Sec-
ond, α-MSH and the tripeptide KPV potently and selectively
reduce membrane binding of IL-1β to T-cell clones [28,29].
This mechanism could be important in our experimental model
as the IL-1β/IL-1R interaction is vital for MSU crystal-induced
inflammation [14].
Preincubation of neutrophils with α-MSH or (CKPV)2 reduced
their ability to migrate toward MSU crystal-induced superna-
tants and to be primed by SMMs, in terms of ROI production.
This agrees with previous observations [9] that melanocortin
peptides inhibit neutrophil chemotaxis toward FMLP and IL-8
and their capacity to generate ROIs in response to phorbol
esters, an effect that is probably related to the peptides' ability
to increase cAMP generation in human neutrophils.
Conclusions
The present experiments indicate that α-MSH and (CKPV)2
have a dual effect on MSU crystal-induced inflammation: they
prevent Mos from producing neutrophil chemoattractants and
activating compounds and inhibit neutrophil responses to
these inflammatory substances. These findings agree with the
observations of Getting and colleagues [15,16], who found
that melanocortins had protective action in a rat model of
gouty arthritis, and suggest a further mechanism for the pro-
tective effect. Our results indicate α-MSH and related pep-
tides as a potential new class of drugs for the treatment of
inflammatory arthritis.
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